
# nexus ag



QUARTERLY REPORT MARCH 31, 2013

## **Letter to Our Stockholders**

Dear Stockholders:



Very pleasing growth in sales and good development of earnings: The NEXUS team was able to show an extremely positive track record in the first quarter 2013.

With sales increases of approx. 20% and improved revenues of approx. 18.1%, we were able to continue our development of increasing sales with a simultaneously high rate of increasing profits in the first quarter 2013.

This is a result, which is not to be taken for granted following the strong growth figures of the last periods. We are profiting from the good demand for our products and also from our newly acquired companies in this first quarter, which are responsible for part of the growth.

Our wide range of products in the meantime is also providing us with additional marketing potential. Today, we can provide our customers with a complete range of market-leading diagnostic information systems in addition to NEXUS / HIS. We also provide complete solutions for rehabilitation institutions and senior citizen homes. This is a tre-

### Highlights Q1 - 2013 Company development

- + Strong increases in sales in the 1st quarter
- + Challenges of HIS project implementation
- + Great number of incoming orders in France
- + Very good development of business in the senior citizen home area

mendous advantage for our customers, because they no longer have to face technical integration aspects and delivery from one source substantially reduces complexity for them.

However, our focus in the first quarter was not so much on sales and marketing, but rather on the challenges that we face in implementing our large projects. We were able to make considerable progress in these projects in the first quarter. We advanced numerous new introductions and development tasks substantially, so that we can meet decisive deadlines this year. Against the background of many new orders, we are extremely satisfied with this situation.

We also started with integration of CoM.Med GmbH in the first quarter, which we acquired on 1 January 2013. With 11 employees, the company develops and markets solutions for administration and billing for rehabilitation clinics in Germany and Austria. Now we can also provide complete solutions for rehabilitation institutions from the NEXUS portfolio, a gap that we have wanted to fill for quite some time.

The first quarter started very well with respect to the number of new orders. We received orders from a total of 86 hospitals, rehabilitation institutions and senior citizen homes. They included a call for bids for a complete hospital system, which we were able to win with NEXUS / HIS. The number of incoming orders greatly increased in France. Seven hospitals decided in favor of our OP documentation or CSSD software. In the area of senior citizen homes, we recorded orders from 33 institutions, especially for software conversions in Switzerland and Germany. Our product E-Qalin started the year very successfully in Austria. Within our diagnostic product groups, we were able to win institutions of the amedes Group for our pathology system and other customers in obstetrics (among others, Aachen University Hospital).

NEXUS is positioned more widely and stably today than in the past. Our incoming orders are smoothing out and coming from different business areas. Consequently, we are able to react very dynamically to different customer groups and the developments in various markets. The increased complexity is also creating very varied challenges, which we have to face in the upcoming months. We have to increase the professionalism of support for our regular customers even further and gain new employees for this area at the same time.

We are looking forward to these challenges and would like to thank you, dear stockholders, for your trust.

Warm regards

n regards

CEO NEXUS AG

Key Figures	03/31/2013		03/31/2012
	KEUR	%	KEUR
Sales	16,604	19,8	13,855
Sales HC-Software	14,509	12,9	12,853
Sales HC-Service	2,095	109,1	1,002
Sales National	9,479	37,3	6,903
Sales International	7,125	2,5	6,952
Result of the period before tax	1,662	18,1	1,407
Result of the period	1,702	20,5	1,413
EBITDA	3,240	17,1	2,767
Result per Share	0,12	20,0	0,10
Investments in intangible and tangible assets	1,299	32,8	978
Depreciation	1,612	9,2	1,476
Liquidity	25,992	-5,0	27,362
Cash Flow from operative activities	4,547	-28,4	6,353
Employees (31 March)	578	18,9	486

## **Interim Annual Report-Sales**

## Report about the Profit, Financial and Asset Situation

NEXUS-Group sales increased in the first three months of the year 2013 from KEUR 13,855 to KEUR 16,604 (+20%).


We were able to achieve especially strong growth in the Healthcare Service area. The business area developed positively, and the sales of the acquired ASS.TEC GmbH, Villingen, were consolidated. Sales increased from KEUR 1,002 to KEUR 2,095. The Healthcare Software segment increased by approx. 12.9% to KEUR 14,509 (Q1-2012: KEUR 12,853); E&L medical systems GmbH, Villingen, was consolidated here for the first time. Without the sales of the companies consolidated for the first time, sales would have increased by 7.1% in the first quarter.


The international share of total business volume was 42.9% (previous year: 50.2%).

In addition to Switzerland, the highest volumes were in France and Austria. We were able to increase sales in Germany by 37.3% to KEUR 9,479 (Q1-2012: KEUR 6,903). The different growth rates in the regions are especially due to billing procedures, but also to the consolidation of the new subsidiaries in the first quarter. Exchange rate fluctuations compared to 2012 were not significant, because the average exchange rate of the Swiss franc as of 31 March 2013 SFR (1.21) only differs slightly from the average rate on 31 December 2012 (SFR 1.21).

We continued the uninterrupted positive development of sales of the NEXUS-Group of many years in the first quarter 2013!

Group (1st Quarter) sales in KEUR +19.8% as of previous year EBIT-development (1st Quarter) in KEUR +18.1% as of previous year






The operating result after taxes improved by approx. 20.5% to KEUR 1,702. Earnings per share amounted to  $\le$  0.12 (Q1-2012:  $\le$  0.10).

The operating result increased by approx. 26.1% and achieved KEUR 1,628 in the first quarter compared to KEUR 1,291 in the previous year. The result before taxes and interest (EBIT) amounted to KEUR 1,662 following KEUR 1,407 (Q1-2012) and increased by approx. 18.1% compared to the previous year. Depreciation of intangible assets, which increased by approx. 9% to KEUR 1,612 (Q1-2012: KEUR 1,476) due the recent acquisitions, affected the result negatively.

4

### EBITDA (1st Quarter) in KEUR +17.1% as of previous year



The EBITDA increased correspondingly to KEUR 3,240 following KEUR 2,767 (+17.1%). One-time effects and expenses for company integrations are represented in their complete amount in the operating result.

Our operative cash flow remained strong at KEUR 4,547 in Q1-2013, but did not reach the high value of the previous year of KEUR 6,353. Special effects played a greater role in this last year.

Investments in the amount of KEUR 1.299 were made (Q1-2012: KEUR 978).

Liquid funds including securities increased by KEUR 2,941 to KEUR 25,992 in the first quarter (31 Dec. 2012: KEUR 23,051).

The balance sheet total increased from KEUR 101,167 to KEUR 105,124 compared to 31 December 2012. There are no essential bank liabilities. Intangible assets and goodwill add up to a total of KEUR 49,241 following KEUR 49,495 (31 Dec. 2012). Receivables from customers decreased from KEUR 19,122 to KEUR 18,790 compared to 31 December 2012.

#### Sales by division

	01/01/ - 03/31/12	01/01/ - 03/31/13	Δ IN %
	KEUR	KEUR	
Healthcare Software	12,853	14,509	12.9
Healthcare Service	1,002	2,095	109.1
Total	13,855	16,604	19.8

# Highlights 1st Quarter - 2013 Group Sales and Operating Result

- + 19.8% sales increase in first quarter 2013 from KEUR 13,855 (Q1-2012) to KEUR 16,604
- + 18.1% increase in result before taxes from KEUR 1,407 (Q1-2012) to KEUR 1,662
- + Strongly positive operative cash flow KEUR 4,547
- + EBITDA increased to KEUR 3,240 (+17.1%)
- + Increase of liquid funds by € 2.9 million to € 25.9 million

#### Sales by region

	01/01/ - 03/31/12	01/01/ - 03/31/13	Δ IN %
	KEUR	KEUR	
Germany	6,903	9,479	37.3
Switzerland	5,744	5,709	-0.6
Austria	295	383	29.8
Italy	2	2	0.0
Rest of world / USA	911	1,031	13.2
Total	13,855	16,604	19.8

#### **Employees**

NEXUS-Group employed a total of 578 people as of 31 March 2013 (Q1-2012: 486 employees). The great majority of the employees (517) work in the Healthcare Software segment. The Health Care Service segment employs 61 people (Q1-2011: 35).

## Innovation: NEXUS-Solutions

### NEXUS / RIS: A Great Leap Forward in Efficiency in Radiology

The new Radiology Information System NEXUS / RIS is based on modern software architecture, which enables fast workflows and short paths. The experience from hundreds of installations has been integrated into state-of-the-art technology  $\frac{1}{2}$ 

with one objective: To save time! It is the newest generation of software, which NEXUS has to offer. With the new NEXUS / RIS, we have made great progress in ergonomy and function strength, a fact that radiologists and MTAs have confirmed. It's about time from the viewpoint of users. The market had not produced any completely new, technologically strong RIS for more than a decade. The customers are correspondingly enthusiastic when they test the new possibilities intensively.

The pre-configured diagnosis of examinations is especially striking. This provides radiologists and doctors with valuable support in structuring their workflows and saves time. NEXUS supplies a novel interface completely adapted to users for

### NEXUS / HIS: Simple - Focused - Fast

NEXUS / HIS is designed on principle to be simple and user-friendly and is based on state-of-the-art technology. Hospital staff access required information with one click thanks to our "One-Click to Information" philosophy. The new generation of hospital information systems enables even faster access to patient data; thanks to the use of mobile solutions, hospital staff have all relevant information on hand at all times. User-defined apps for medicine and care simplify everyday hospital work and are redundant throughout the system.


## **Established Software Solution** Supports CSSD: Modern -**Comprehensive - Field-Proven**

The NEXUS solution for the sterilization process supports and guides the staff via touch control in mastering / SPM completely controls the cleaning workflow in the CSSD and comprehensively documents preparation of

## **NEXUS / PDMS: Equipment inte**gration in intensive care medicine

A patient management system cannot be a standalone system anymore today, but instead has to be integrated into a HIS with respect to functionality and ergonomy. This is the reason why NEXUS / PDMS was developed as an integral component of NEXUS / HIS - including equipment links.

NEXUS / PDMS is not just an information system in this context, but also a communication system. The processes of intensive care medicine are depicted comprehensively. As a result, drug prescriptions, care process planning, entry of services performed, billing and display of the patient chart are performed using the standard module of the NEXUS / HIS solution. The advantage: doctors and nurses can find what they want more easily, because the same applications are used on wards and in intensive care. Access to the patient chart is retained when a patient is moved from intensive care. NEXUS has broken down the wall between intensive care solutions and HIS with this innovative approach.



# **NEXUS** Company Information and Outlook

#### **Chances and Risks**

Please refer to the explanations in the annual report of 31 December 2012 for information about the essential chances and risks in the development of NEXUS-Group. There have been no essential changes in the meantime.

#### **Outlook: Positive pulses**

We were able to finish the first quarter 2013 very successfully continuing our unabated positive development of the last years. Sales increases of 19.8% and an increase of the Group result of 18.1% and a strong operative cash flow are pleasing results. Although we already had outstanding increase rates in the previous years, we are still able to improve our figures continually.

The penetration of new markets and business areas is significant, something that we have been pushing consistently for the past two years with product developments and company acquisitions. This is creating great potential, but also challenges to which we have to dedicate ourselves with tremendous intensity. We will have to prove during the next periods that we can continue to improve and expand our revenue picture in spite of these considerable investments.

We already see a lot of positive results in our new business areas and are very optimistic concerning the rest of 2013 thanks to our strong product portfolio and our good order situation.

### **Directors Holdings**

The director's holders of the Supervisory Board and the Executive Board are as follows on 31 March 2013 in comparison to the previous year:

	Numbers of stock owned	Numbers of options
Superviory Board		
Dr. jur. Hans-Joachim König	101,239 Prev. year (101,239)	0 Prev. year (0)
Prof. Dr. Alexander Pocsay	121,500 Prev. year (121,500)	0 Prev. year (0)
Erwin Hauser	15,000 Prev. year (15,000)	0 Prev. year (0)
Matthias Gaebler	0 Prev. year (0)	0 Prev. year (0)
Master of Business Administration (FH) Wolfgang Dörflinger	0 Prev. year (0)	0 Prev. year (0)
Prof. Dr. Ulrich Krystek	0 Prev. year (0)	0 Prev. year (0)
Executive Board		
Dr. Ingo Behrendt (MBA)	169,000 Prev. year (169,000)	0 Prev. year (0)
Ralf Heilig (MBA)	135,350 Prev. year (135,350)	0 Prev. year (0)
Edgar Kuner (Graduate Engineer)	248,051 Prev. year (253,051)	0 Prev. year (0)


#### **ACOUNTING AND VALUATION METHODS**

This interim report from the NEXUS-Group of 31 March 2013 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretation of the International Financial Reporting Interpretation Committee (IFRIC) has been taken into account.

The regulations of IAS 34 have been observed in the interim report of 31 March 2013. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2012. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2012.

The report has not been audited.

# **NEXUS** in the environment of the financial and health markets



Following a stock price leap from €9.10 to €9.69 on 28 December at the end of 2012, NEXUS shares started the year 2013 at an initially listed price of €9.49. The price declined in January to the September level of the prior year from €9.20 to €8.70. The price decreased to its lo-

(status quo: may `13)	
General stockholders meeting, Stuttgart (D	13 May
Half-year Report	19 August
Quarterly Report - third quarter	11 November
German equity forum, Frankfurt (D)	11 - 13 November
HIT, Paris (F)	09 - 12 May
Jahrestagung Radioonkologie, Berlin (D)	09 - 12 May
Jahrestagung Pathologie, Heidelberg (D)	23 - 26 May
Deutscher Roentgenkongress, Berlin (D)	29 - 01 June
IFAS, Lausanne (CH)	30 - 01 November
MEDICA & BeraterDialog, Düsseldorf (D)	20 - 23 November

Finance- and event schedule 2013

west point of €8.69 in the time leading into February. NEXUS shares recovered in February to the second highest price until now and were listed at €9.34. NEXUS shares rose sharply for a short time at the time of publishing the annual report 2012 on 25 March. Publication of the invitation to the annual stockholders meeting at the beginning of April with the proposal to pay a dividend of €0.11 per share affected the price negatively (€8.63) after a direct rise (€9.12). Afterward, the stock price moved to a great extent within a range parallel to the TecDax in a sideways tendency around €9.00.

### **Decisions for NEXUS 2013**

- + Universitätsklinikum Aachen, Aachen (D)
- + Alters- und Pflegeheim, Adliswil (CH)
- + Centre Clinical Soyaux, Angoulême (F)
- + MVZ Radiologie & Nuklearmedizin, Aschaffenburg (D)
- + Schussental-Klinik, Aulendorf (D)
- + ZfP Südwürttemberg, Bad Schussenried (D)
- + Domicil Schwabgut, Bern (CH)
- + Gosmergartä, Bürglen (CH)
- + Pflegedienst Rolf Hansen, Düsseldorf (D)
- + Micura Pflegedienst, Bremen (D)
- + Normanni Sante, Colombelles (F)
- + Polyclinique Pays de Rance, Dinan (F)
- + Diakonie-Krankenhaus Harz, Elbingerode (D)
- + Salem, Ennenda (CH)
- + Marien-Hospital, Euskirchen (D)
- + Alterszentrum am Etzel, Feusisberg (CH)
- + Alters- und Pflegeheim Gelterkinden, Gelterkinden (D)
- + Betagtensiedlung D'r Heimä, Giswil (CH)
- + amedes Gruppe, Standorte Göttingen / Einbeck (D)
- + La Vita, Goldach (CH)
- + Krankenhaus Oranienburg, Hennigsdorf Oberhavel (D)
- + Mathilden Hospital, Herford (D)
- + Seniorenzentrum Schweizerhof, Kandersteg (CH)
- + Heim Ibenmoos, Kleinwangen (CH)
- + Bethesda Pflegeresidenz, Küsnacht (CH)
- + Centre Hospitalier de Lisieux, Lisieux (F)
- + Eyhuis Lungern, Lungern (CH)
- + Vorwerker Diakonie, Lübeck (D)
- + Senesca und Spitex, Maienfeld (CH)
- + Universitätsfrauenklinik, Mainz (D)
- Klinikum Memmingen, Memmingen (D)

- + Centre Hospitalier Intercommunal, Meulan Les Mureaux (F)
- + Minden Mühlenkreiskliniken, Minden (D)
- + Gemeinschaftspraxis Dr. Dienemann / Dr. Hölzl / Fr. Dr. Eisenlohr, München (D)
- + Alters- und Pflegeheim Glarus Nord, Näfels (CH)
- + Polyclinique St Augustin, Nantes (F)
- + Pflegeheim Neuenhof, Neuenhof (CH)
- + Evangelisches Fachkrankenhaus, Neustadt (D)
- + Maternite de L'etoile, Puyricard (F)
- + Haus zur Heimat, Olten (CH)
- + Oberhavel Kliniken, Oranienburg (D)
- + Polyclinique de Poitiers, Poitiers (F)
- + EVK Rheinland (2 Kliniken) (D)
- + Helios Kliniken, Rottweil (D)
- + Med. Versorgungszentrum Kloster Paradiese, Soest (D)
- + Polyclinique de L'Atlantique, St Herblain (F)
- + Louis-Constant Fleming Hospital, St Martin (IS)
- + St. Annaheim, Steinerberg (D)
- + Bindersgarten, Tägerwielen (CH)
- + Bergheim Uetikon, Uetikon am See (CH)
- + Alterszentrum Frohmatt, Wädenswil (CH)
- + Gen. Im Spilhöfler Uitikon, Waldegg (CH)
- + Harz-Klinikum Wernigerode-Blankenburg GmbH, Standorte Wernigerode / Quedlinburg (D)
- + RNS Gemeinschaftspraxis GbR, Wiesbaden (D)
- + ThurVita AG, Will (CH)
- + Spitex Willisau, Willisau (CH)
- + Universitätsklinikum Würzburg, Würzburg (D)
- + 10 Häuser der SeneCura-Gruppe in Austria (D)
- + Haus Stritzl, Wandersloh (D)

# Facts and Figures Group P+L Account as of 03/31/2013 and 03/31/2012 (IFRS)

Group statement of income and accumulated earnings	03/31/2013	03/31/2012
	KEUR	KEUR
Revenue	16,604	13,855
Changes in inventories of finished goods and work in progress	6	0
Development work capitalized	1,265	910
Other operating income	438	423
Cost of materials including purchased services	3,589	1,870
Personnel costs	9,425	8,300
Depreciation	1,612	1,476
Other operating expenses	2,059	2,251
Operating result	1,628	1,291
Results of equity-accounted investments	1	0
Finance Income	76	167
Finance Expenses	43	51
Result before tax on profit	1,662	1,407
Taxes on profit	-40	-6
Consolidated result	1,702	1,413
Of the period result, attributed to: - Stockholders of NEXUS AG - Minority interests	1,843 -141	1,452 -39
Period result per share in KEUR		
Weighted average of issued shares in circulation (in thousands) - simple - diluted	15,064 0,12 0,12	14,284 0,10 0,10

# Group statement of income and accumulated earnings as of

03/31/2013 and 12/31/2012

	03/31/2013	12/31/2012
	KEUR	KEUR
Consolidated result	1,702	1,413
Actuarial profits and losses (after taxes on profit)	-14	-21
Differences from the conversion of foreign currency (after taxes on profit)	356	-145
Market value changes from assets available for sale (after taxes on profit)	-1	0
Other Overall Result	341	-166
Overall Result of the Period	2,043	1,247
Of the overall result, attributed to:		
- Stockholders of NEXUS AG	2,184	1,286
- Minority interests	-141	-39

# Facts and Figures Balance sheet as of 03/31/2013 and 12/31/2012 (IFRS)

Assets	03/31/2013	12/31/2012
	KEUR	KEUR
LONG-TERM ASSETS		
Goodwill	25,121	25,227
Other intangible assets	24,120	24,267
Fixed assets	1,865	1,925
Shares in affiliated companies	83	43
Credited deferred taxes	4,250	4,174
Other financial assets	91	131
Total of long-term assets	55,530	55,767
Short-term assets		
Inventories	286	414
Trade receivables and other receivables	18,828	19,144
Receivables from tax on profits	669	509
Other non-financial assets	2,155	1,153
Other financial assets	1,664	1,129
Short-term financial assets	10,106	10,145
Cash and balance in bank	15,886	12,906
Total of short-term assets	49,594	45,400
Total assets	105,124	101,167

Equity and liabilities	03/31/2013	12/31/2012
	KEUR	KEUR
Capital and accruals		
Subscribed capital	15,105	15,105
Capital reserves	25,757	25,757
Net loss for the year	28,524	22,398
Consolidated net income	1,843	6,128
Other cumulated Group result	-1,230	-861
Own shares	-293	-296
Equity capital attributable to stockholders of the parent company	69,706	68,231
Minority interests	-211	-118
Total equity	69,495	68,113
Long-term debts		
Pension obligations	2,678	2,597
Debited deferred taxes	3,844	3,840
Other financial assets	5,030	5,030
Total of long-term debts	11,552	11,467
Short-term debts		
Accruals	553	1,315
Financial liabilities	117	385
Trade accounts payable	3,505	4,079
Liabilities from tax on profit	516	513
Deferred revenue liability	8,787	3,569
Other non-financial debts	6,577	8,132
Other financial debts	4,022	3,594
Total of short-term debts	24,077	21,587
Total assets	105,124	101,167

# Facts and Figures Consolidated cash flow statement 03/31/2013 and 03/31/2012 (IFRS)

	2013	2012
	KEUR	KEUR
1. Cash Flow from Current Business Transactions		
Group annual result before tax on income	1,662	1,407
Depreciation and amortization of intangible assets and plant, equipment and other fixed assets	1,612	1,476
Other expenses/income with no impact on cash	39	-53
Increase/decrease in inventories	128	-95
Increase/decrease in trade receivables and other assets that cannot be allocated to investing or financing activities	-1,434	-335
Increases and decreases of accruals insofar as not entered in equity capital	-725	-115
Increase/decrease in trade receivables and other liabilities that cannot be allocated to investing or financing activities	3,194	3,959
Paid interest	-1	-51
Received interest	90	207
Income taxes paid	-21	-50
Income taxes received	3	3
	4,547	6,353
2. Cash Flow from Investment Activities		
Cash paid for investments in intangible and fixed assets	-1,299	-978
	-1,299	-978
3. Cash Flow from Financing Activities		
Amount paid out for redeeming loans	-268	-71
Erwerb eigener Anteile	0	-10
	-268	-81
4. Amount of cash and cash equivalents at end of period		
Cash relevant changes in cash and cash equivalents (sum of $1 + 2 + 3$ )	2,980	5,294
Cash and cash equivalents at beginning of fiscal year	12,521	12,033
	15,501	17,327
5. Composition of cash and cash equivalents		
Cash on hand	15,618	17,327
Bank liabilities due on demand	-117	0
	15,501	17,327
	10,001	11,021

#### 13

# Facts and Figures Change in equity calculation as of 03/31/2013 and 03/31/2012 (IFRS)

Group Equity Change Statement	Subscribed capital	ACApital reserves	Equity diference from curency conversion	BReserve for financial Instruments	NESERVE for pensions	Consolidated loss carry forward	Consolidated deficit / profit	Uwn Shares	Equity cap, attributable to stockh of parent	Minority interest	NA Total equity	Authori zed capital
Consolidated equity as of 12/31/2011	14,305	19,553	1,192	0	-1,058	19,155	4,770	-46	57,871	284	58,155	6,488
Transfer of 2011 consolidated loss to consolidated loss carry-forward						4,770	-4,770		0		0	
Total of the result entered directly into equity capital			-199	0	-21				-220	54	-166	
Erwerb eigener Anteile		-75						-10	-85		-85	
Overall Result 2012	0	-75	-199	0	-21	4,770	-4,770	-10	-305	54	-251	
Consolidated net income 2012							1,452		1,452	-39	1,413	
Overall Result of period	0	-75	-199	0	-21	4,770	-3,318	-10	1,147	15	1,162	
Consolidated equity as of 03/31/2012	14,305	19,478	993	0	-1,079	23,924	1,452	-56	59,017	299	59,316	6,488
Consolidated equity as of 12/31/2012	15,105	25,757	1,076	-310	-1,627	22,398	6,128	-296	68,231	-118	68,113	6,353
Profit before tax 2012 entered directly in accumulated deficit						6,128	-6,128		0		0	
Total of the result entered directly into equity capital			-356	-1	-14			3	-368		-368	
Overall Result of the Period	0	0	-356	-1	-14	6,128	-6,128	3	-368	0	-368	
Consolidated net income 2013							1,843		1,843	-93	1,750	
Overall Result of period	0		-356	-1	-14	6,128	-6,128	3	1,475	-93	1,382	
Consolidated equity as of 03/31/2013	15,105	25,757	720	-311	-1,641	28,526	1,843	-293	69,706	-211	69,495	6,353

### Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, May 10th, 2013

NEXUS AG Executive Board



NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888 www.nexus-ag.de, info@nexus-ag.de